Disease Analysis: Head and Neck Cancer

  • ID: 3797429
  • Report
  • 309 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Head and neck cancer is the sixth most common cancer worldwide, and includes malignancies that can originate in the oral cavity, salivary glands, sinuses, and throat. Around 90% of cases have an epithelial origin, which present as squamous cell carcinomas. Environmental factors such as tobacco smoking and alcohol consumption greatly increase the risk of developing head and neck cancers. If diagnosed at an early stage, treatment for these cancers can be curative; however, the majority of patients are diagnosed when the disease is advanced, resulting in the need for more than one treatment modality.

Market Snapshot
  • The head and neck cancer market is projected to reach $2.8bn in value by 2026, with growth driven by immunotherapies.
  • Erbitux continues to be the primary targeted therapy prescribed for the treatment of advanced head and neck cancer.
  • The incident population of this common cancer is predicted to increase over the forecast period of 2016-36.
  • Erbitux’s position as the leading targeted therapy for SCCHN is being challenged as immunotherapies enter the market.
  • Immunotherapy developers will look to minimize direct competition in SCCHN by targeting new patient settings.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: HEAD AND NECK CANCER (Published on 01 December 2017)
EXECUTIVE SUMMARY
RECENT FORECAST UPDATES
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
PRODUCT PROFILE (LATE STAGE): BAVENCIO
PRODUCT PROFILE: ERBITUX
PRODUCT PROFILE (LATE STAGE): GILOTRIF
PRODUCT PROFILE (LATE STAGE): IMFINZI
PRODUCT PROFILE: KEYTRUDA
PRODUCT PROFILE (LATE STAGE): MULTIKINE
PRODUCT PROFILE: OPDIVO
BIBLIOGRAPHY

TREATMENT: HEAD AND NECK CANCER (Published on 15 September 2017)
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS

EPIDEMIOLOGY: HEAD AND NECK CANCER (Published on 08 August 2017)
EXECUTIVE SUMMARY
DISEASE BACKGROUND
METHODOLOGY
FORECAST
EPIDEMIOLOGIST INSIGHT
STRENGTHS AND LIMITATIONS
BIBLIOGRAPHY
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: HEAD AND NECK CANCER (Published on 01 December 2017)
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
PRODUCT PROFILE: ERBITUX
PRODUCT PROFILE: KEYTRUDA
PRODUCT PROFILE: OPDIVO

PIPELINE: HEAD AND NECK CANCER (Published on 01 December 2017)
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
PRODUCT PROFILE (LATE STAGE): BAVENCIO
PRODUCT PROFILE (LATE STAGE): GILOTRIF
PRODUCT PROFILE (LATE STAGE): IMFINZI
PRODUCT PROFILE (LATE STAGE): MULTIKINE

List of Figures
Figure 1: SCCHN - current and future market dynamics analysis
Figure 2: The author’s assessment summary of key marketed and pipeline drugs for SCCHN
Figure 3: SCCHN market value across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: SCCHN market value across the US, Japan, and five major EU markets, by class, 2017-26
Figure 5: Sales of PD-1/PD-L1 inhibitors for SCCHN across the US, Japan, and five major EU markets, by brand, 2017-26
Figure 6: Sales of key therapies for SCCHN across the US, Japan, and five major EU markets, by status, 2017-26
Figure 7: Patient-based forecast methodology for SCCHN
Figure 8: Price sources and calculations, by country
Figure 9: Bavencio for head and neck cancer - SWOT analysis
Figure 10: Drug assessment summary of Bavencio for SCCHN
Figure 11: Drug assessment summary of Bavencio for SCCHN
Figure 12: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 13: Erbitux for head and neck cancer - SWOT analysis
Figure 14: Drug assessment summary of Erbitux for SCCHN
Figure 15: Drug assessment summary of Erbitux for SCCHN
Figure 16: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 17: Gilotrif for head and neck cancer - SWOT analysis
Figure 18: Drug assessment summary of Gilotrif for SCCHN
Figure 19: Drug assessment summary of Gilotrif for SCCHN
Figure 20: Gilotrif sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 21: Imfinzi for head and neck cancer - SWOT analysis
Figure 22: Drug assessment summary of Imfinzi for SCCHN
Figure 23: Drug assessment summary of Imfinzi for SCCHN
Figure 24: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 25: Keytruda for head and neck cancer - SWOT analysis
Figure 26: Drug assessment summary of Keytruda for SCCHN
Figure 27: Drug assessment summary of Keytruda for SCCHN
Figure 28: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 29: Multikine for head and neck cancer - SWOT analysis
Figure 30: Drug assessment summary of Multikine for SCCHN
Figure 31: Drug assessment summary of Multikine for SCCHN
Figure 32: Multikine sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 33: Opdivo for head and neck cancer - SWOT analysis
Figure 34: Drug assessment summary of Opdivo for SCCHN
Figure 35: Drug assessment summary of Opdivo for SCCHN
Figure 36: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 37: HPV screening rates and outcomes among SCCHN patients, by country
Figure 38: Proportion of prevalent SCCHN patients in each stage of disease, by country
Figure 39: Proportion of Stage I and Stage II SCCHN patients receiving each treatment type, by country
Figure 40: Percentage of Stage III SCCHN patients receiving each treatment type, by country
Figure 41: Percentage of Stage III SCCHN patients receiving neoadjuvant therapy, adjuvant therapy, or both, by country
Figure 42: Top three regimens used in the adjuvant treatment of Stage III SCCHN patients, by country
Figure 43: Percentage of Stage IV SCCHN patients receiving each treatment type, by country
Figure 44: Top three regimens used in the first-line treatment of Stage IV SCCHN patients who receive pharmacological therapy without surgery, by country
Figure 45: Percentage of Stage IV SCCHN patients who progress from first- to second-line therapy or from second- to thirdline therapy, by country
Figure 46: Top three regimens used for the second-line treatment of Stage IV SCCHN patients, by country
Figure 47: Percentage of local relapse SCCHN patients receiving each treatment type, by country
Figure 48: Top three regimens used in the first-line treatment of local relapse SCCHN patients receiving pharmacological therapy without surgery, by country
Figure 49: Top three regimens used in the second-line treatment of local relapse SCCHN patients, by country
Figure 50: Percentage of distant relapse SCCHN patients receiving each treatment type, by country
Figure 51: Top three regimens used in the first-line treatment of distant relapse SCCHN patients who receive pharmacological therapy without surgery, by country
Figure 52: Top three regimens used in the second-line treatment of distant relapse SCCHN patients, by country
Figure 53: Trends in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
Figure 54: Absolute change in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
Figure 55: Age-specific trends in incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
Figure 56: Erbitux for head and neck cancer - SWOT analysis
Figure 57: Drug assessment summary of Erbitux for SCCHN
Figure 58: Drug assessment summary of Erbitux for SCCHN
Figure 59: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 60: Keytruda for head and neck cancer - SWOT analysis
Figure 61: Drug assessment summary of Keytruda for SCCHN
Figure 62: Drug assessment summary of Keytruda for SCCHN
Figure 63: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 64: Opdivo for head and neck cancer - SWOT analysis
Figure 65: Drug assessment summary of Opdivo for SCCHN
Figure 66: Drug assessment summary of Opdivo for SCCHN
Figure 67: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 68: Bavencio for head and neck cancer - SWOT analysis
Figure 69: Drug assessment summary of Bavencio for SCCHN
Figure 70: Drug assessment summary of Bavencio for SCCHN
Figure 71: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 72: Gilotrif for head and neck cancer - SWOT analysis
Figure 73: Drug assessment summary of Gilotrif for SCCHN
Figure 74: Drug assessment summary of Gilotrif for SCCHN
Figure 75: Gilotrif sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 76: Imfinzi for head and neck cancer - SWOT analysis
Figure 77: Drug assessment summary of Imfinzi for SCCHN
Figure 78: Drug assessment summary of Imfinzi for SCCHN
Figure 79: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 80: Multikine for head and neck cancer - SWOT analysis
Figure 81: Drug assessment summary of Multikine for SCCHN
Figure 82: Drug assessment summary of Multikine for SCCHN
Figure 83: Multikine sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: SCCHN market value across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 2: SCCHN market value across the US, Japan, and five major EU markets, by class ($m), 2017-26
Table 3: Sales of PD-1/PD-L1 inhibitors for SCCHN across the US, Japan, and five major EU markets, by brand ($m), 2017-26
Table 4: Sales of key therapies for SCCHN across the US, Japan, and five major EU markets, by status ($m), 2017-26
Table 5: Summary of drug classes and molecules included in the author’s SCCHN patient-based forecast
Table 6: Exchange rates used for calculating prices
Table 7: Patent expiry dates for key marketed brands in SCCHN across the US, Japan, and five major EU markets, 2017-26
Table 8: Estimated launch dates of key pipeline products and marketed brands in SCCHN across the US, Japan, and five major EU markets, 2017-26
Table 9: Medical oncologists, otolaryngologists, and ENT surgeons surveyed for the head and neck cancer primary research study, 2017
Table 10: Bavencio drug profile
Table 11: Bavencio Phase III trials in head and neck cancer
Table 12: Bavencio early-phase data in head and neck cancer
Table 13: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 14: Bavencio patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 15: Erbitux drug profile
Table 16: Erbitux pivotal trial data in head and neck cancer
Table 17: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 18: Erbitux patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 19: Gilotrif drug profile
Table 20: Gilotrif Phase III trials in head and neck cancer
Table 21: Gilotrif Phase III trial data in head and neck cancer
Table 22: Gilotrif early-phase data in head and neck cancer
Table 23: Gilotrif sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 24: Gilotrif patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 25: Imfinzi drug profile
Table 26: Imfinzi Phase III trials in head and neck cancer
Table 27: Imfinzi early-phase data in head and neck cancer
Table 28: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 29: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 30: Keytruda drug profile
Table 31: Keytruda pivotal trial data in head and neck cancer
Table 32: Keytruda ongoing late-phase trials in head and neck cancer
Table 33: Keytruda early-phase data in head and neck cancer
Table 34: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 35: Keytruda patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 36: Multikine drug profile
Table 37: Multikine Phase III trials in head and neck cancer
Table 38: Multikine early-phase data in head and neck cancer
Table 39: Multikine sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 40: Multikine patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 41: Opdivo drug profile
Table 42: Opdivo pivotal trial data in head and neck cancer
Table 43: Opdivo ongoing late-phase trials in head and neck cancer
Table 44: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 45: Opdivo patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 46: Physicians surveyed for the head and neck cancer primary research study, 2017
Table 47: Oral cavity and pharynx cancer five-year survival rates, by stage at diagnosis, 2007-13
Table 48: TNM stage classification
Table 49: Leading treatments for SCCHN
Table 50: Head and neck cancer site codes according to ICD-10
Table 51: Cancer registry databases used as a source of HNC incidence data, by country
Table 52: Forecasting methodology for HNC incidence, by country, age group, and gender
Table 53: Sources of survival data used to estimate HNC prevalence, by country/region
Table 54: Diagnosed incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
Table 55: Age-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
Table 56: Gender-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
Table 57: Validation of forecast estimates against benchmark estimates
Table 58: Profiled key marketed drugs for head and neck cancer
Table 59: Erbitux drug profile
Table 60: Erbitux pivotal trial data in head and neck cancer
Table 61: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 62: Erbitux patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 63: Keytruda drug profile
Table 64: Keytruda pivotal trial data in head and neck cancer
Table 65: Keytruda ongoing late-phase trials in head and neck cancer
Table 66: Keytruda early-phase data in head and neck cancer
Table 67: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 68: Keytruda patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 69: Opdivo drug profile
Table 70: Opdivo pivotal trial data in head and neck cancer
Table 71: Opdivo ongoing late-phase trials in head and neck cancer
Table 72: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 73: Opdivo patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 74: Profiled pipeline products in development for head and cancer
Table 75: Bavencio drug profile
Table 76: Bavencio Phase III trials in head and neck cancer
Table 77: Bavencio early-phase data in head and neck cancer
Table 78: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 79: Bavencio patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 80: Gilotrif drug profile
Table 81: Gilotrif Phase III trials in head and neck cancer
Table 82: Gilotrif Phase III trial data in head and neck cancer
Table 83: Gilotrif early-phase data in head and neck cancer
Table 84: Gilotrif sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 85: Gilotrif patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 86: Imfinzi drug profile
Table 87: Imfinzi Phase III trials in head and neck cancer
Table 88: Imfinzi early-phase data in head and neck cancer
Table 89: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 90: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 91: Multikine drug profile
Table 92: Multikine Phase III trials in head and neck cancer
Table 93: Multikine early-phase data in head and neck cancer
Table 94: Multikine sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 95: Multikine patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll